Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring adenocarcinoma of the prostate, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer, stage IV prostate cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate High-risk, locally advanced disease (T2b-T4 disease), meeting 1 of the following criteria: Gleason score 8-10 Prostate-specific antigen > 20 ng/dL AND Gleason score 7 T2a disease allowed provided ≥ 5 biopsies contain Gleason score 4 +3 cancer (minimum of 10 biopsies total required) No evidence of metastatic disease within the past 60 days by physical examination, chest x-ray, bone scan, and CT scan of abdomen and pelvis PATIENT CHARACTERISTICS: ECOG performance status 0-2 Hemoglobin > 8 g/dL Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 times upper limit of normal (ULN) Creatinine ≤ 1.5 times ULN Blood pressure ≤ 150/100 mm Hg No cardiovascular disease, including any of the following: Unstable angina New York Heart Association class II-IV congestive heart failure History of myocardial infarction within the past 6 months History of stroke within the past 6 months PRIOR CONCURRENT THERAPY: At least 4 weeks since prior major surgery No prior hormonal therapy (except finasteride for obstructive voiding symptoms) for prostate cancer No prior or concurrent chemotherapy, biologic therapy, or radiotherapy for prostate cancer
Sites / Locations
- Benaroya Research Institute at Virginia Mason Medical Center